Antagonist properties of a phosphono isoxazole amino acid at glutamate R1-4 (R,S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid receptor subtypes

被引:25
|
作者
Wahl, P
Anker, C
Traynelis, SF
Egebjerg, J
Rasmussen, JS
Krogsgaard-Larsen, P
Madsen, U
机构
[1] Novo Nordisk AS, Dept Mol Pharmacol, DK-2760 Maaloev, Denmark
[2] Emory Univ, Dept Pharmacol, Atlanta, GA 30322 USA
[3] Novo Nordisk AS, Dept Mol Genet, DK-2880 Bagsvaerd, Denmark
[4] Royal Danish Sch Pharm, Dept Med Chem, DK-2100 Copenhagen, Denmark
关键词
D O I
10.1124/mol.53.3.590
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The activity of the (R,S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid (AMPA) receptor antagonist, (R,S)-2-amino-3-[5-tert-butyl-3-(phosphonomethoxy)-4-isoxazolyl]propionic acid (ATPO), at recombinant ionotropic glutamate receptors (GluRs) was evaluated using electrophysiological techniques, Responses at home-or heterooligomeric AMPA-preferring GluRs expressed in human embryonic kidney (HEK) 293 cells (GluR1-flip) or Xenopus laevis oocytes (GluR1-4-flop or GluR1-flop + GluR2) were potently inhibited by ATPO with apparent dissociation constants (K-b values) ranging from 3.9 to 26 mu M. A Schild analysis for kainate (KA)-activated GluR1 receptors showed ATPO to have a K-B of 8.2 mu M and a slope of unity, indicating competitive inhibition. The antagonism by ATPO at GluR1 was of similar magnitude at holding potentials between -100 mV and +20 mV. In contrast, ATPO (<300 mu M), does not inhibit responses to kainate at homomeric GluR6 or heterooligomeric GluR6/KA2 expressed in HEK 293 cells but activated GluR5 and GluR5/KA2 expressed in X. laevis oocytes. ATPO produced <15% inhibition at the maximal concentration (300 mu M) of current responses through NR1A + NR2B receptors expressed in X. laevis oocytes. Thus, ATPO shows a unique pharmacological profile, being an antagonist at GluR1-4 and a weak partial agonist at GIuR5 and GluR5/KA2.
引用
收藏
页码:590 / 596
页数:7
相关论文
共 50 条
  • [1] Development of Novel PET Probes for Central 2-Amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic Acid Receptors
    Oi, Norihito
    Tokunaga, Masaki
    Suzuki, Michiyuki
    Nagai, Yuji
    Nakatani, Yosuke
    Yamamoto, Noboru
    Maeda, Jun
    Minamimoto, Takafumi
    Zhang, Ming-Rong
    Suhara, Tetsuya
    Higuchi, Makoto
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (21) : 8444 - 8462
  • [2] Studies on an (S)-2-Amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic Acid (AMPA) Receptor Antagonist IKM-159: Asymmetric Synthesis, Neuroactivity, and Structural Characterization
    Juknaite, Lina
    Sugamata, Yutaro
    Tokiwa, Kazuya
    Ishikawa, Yuichi
    Takamizawa, Satoshi
    Eng, Andrew
    Sakai, Ryuichi
    Pickering, Darryl S.
    Frydenvang, Karla
    Swanson, Geoffrey T.
    Kastrup, Jette S.
    Oikawa, Masato
    JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (06) : 2283 - 2293
  • [3] Structural basis for 2-amino-3-(3-hydroxy-5methyl-4-isoxazolyl)propionic acid (AMPA) receptor activation
    Johansen, TN
    Greenwood, JR
    Vogensen, SB
    Krogsgaard-Larsen, P
    PURE AND APPLIED CHEMISTRY, 2004, 76 (05) : 921 - 930
  • [4] MOLECULAR PHARMACOLOGY OF THE AMPA AGONIST, (S)-2-AMINO-3-(3-HYDROXY-5-PHENYL-4-ISOXAZOLYL)PROPIONIC ACID [(S)-APPA] AND THE AMPA ANTAGONIST, (R)-APPA
    EBERT, B
    MADSEN, U
    LUND, TM
    LENZ, SM
    KROGSGAARDLARSEN, P
    NEUROCHEMISTRY INTERNATIONAL, 1994, 24 (06) : 507 - 515
  • [5] Ab Initio studies of receptor interactions with AMPA ((S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl) propionic acid ) and Kainic acid (2S-(2α,3β,4β))-2-carboxy-4-(1-methylethenyl)-3-pyrrolidineacetic acid
    Champeil, Elise
    Proni, Gloria
    Sapse, Danielle
    JOURNAL OF MOLECULAR MODELING, 2009, 15 (09) : 1109 - 1117
  • [6] Ab Initio studies of receptor interactions with AMPA ((S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl) propionic acid ) and Kainic acid (2S-(2α,3β,4β))-2-carboxy-4-(1-methylethenyl)-3-pyrrolidineacetic acid
    Elise Champeil
    Gloria Proni
    Danielle Sapse
    Journal of Molecular Modeling, 2009, 15 : 1109 - 1117
  • [7] Convergent synthesis and pharmacology of substituted tetrazolyl-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid analogues
    Vogensen, SB
    Clausen, RP
    Greenwood, JR
    Johansen, TN
    Pickering, DS
    Nielsen, B
    Ebert, B
    Krogsgaard-Larsen, P
    JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (09) : 3438 - 3442
  • [8] Search for noncompetitive 2-amino-3(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid receptor (AMPAR) antagonists: Synthesis, pharmacological properties, and computational studies
    Chimirri, A
    De Sarro, G
    Quartarone, S
    Barreca, ML
    Caruso, R
    De Luca, L
    Gitto, R
    PURE AND APPLIED CHEMISTRY, 2004, 76 (05) : 931 - 939
  • [9] Structural dynamics in a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor gating
    Gonzalez, Cuauhtemoc U.
    Jayaraman, Vasanthi
    CURRENT OPINION IN STRUCTURAL BIOLOGY, 2024, 87
  • [10] SYNTHESIS AND PHARMACOLOGY OF (RS)-2-AMINO-3-(3-HYDROXY-5-TRIFLUOROMETHYL-4-ISOXAZOLYL)PROPIONIC ACID, A POTENT AMPA RECEPTOR AGONIST
    MADSEN, U
    EBERT, B
    KROGSGAARDLARSEN, P
    WONG, EHF
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 1992, 27 (05) : 479 - 484